BioAtla, Inc.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
BCAB$1.74-44.7%Stored close · as of Aug 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(69,776) | $(123,462) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 925 | 1,221 |
| Loss on disposal of property and equipment | — | 2 |
| Change in fair value of warrant liability | (807) | — |
| Stock-based compensation | 8,921 | 13,544 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 2,903 | (11) |
| Accounts payable and accrued expenses | (13,461) | 5,284 |
| Right-of-use assets and lease liabilities, net | (641) | (593) |
| Net cash used in operating activities | (71,936) | (104,015) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | — | (98) |
| Net cash used in investing activities | — | (98) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock and warrants, net of issuance costs | 9,215 | — |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | 342 | 336 |
| Payments for taxes related to net settlement of equity awards | (46) | (259) |
| Net cash provided by financing activities | 9,511 | 77 |
| Net decrease in cash and cash equivalents | (62,425) | (104,036) |
| Cash and cash equivalents, beginning of period | 111,471 | 215,507 |
| Cash and cash equivalents, end of period | $49,046 | $111,471 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Equity issuance costs included in accounts payable and accrued expense | $445 | $— |
| Tax related to net settlement of equity awards included in accounts payable and accrued expenses | $— | $6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.